# NA Vaccine Institute

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/na-vaccine-institute

- Industry: Healthcare Specialists
- Headquarters: Seoul, South Korea
- Website: www.navaccine.org
- Total disclosed funding: $14M
- Latest round: Series B (Nov 19, 2021)
- Investors on record: 10

## About

NA Vaccine Institute is dedicated to developing innovative vaccines and therapeutic solutions to address health challenges. Their work encompasses advanced immunology and therapeutic strategies aimed at improving health outcomes across various sectors.Founded in 2018, NA Vaccine Institute operates from Seoul, South Korea and specializes in vaccine development. The firm has successfully executed three deals, with the most recent being on November 18, 2021, when it raised KRW 17 billion in Series B funding led by investors including DS Asset Management and DSC Investment. The company was founded by Dongho Kim, who serves as the CEO. He has a track record in the biotech field, contributing to advancements in vaccine technology.NA Vaccine Institute focuses on the development of innovative vaccines and therapeutic solutions aimed at addressing various health challenges. Their core product offerings include Nexavant®, an immune enhancer, and PeptoVac®, a vaccine designed to bolster the body's defenses against pathogens. Additionally, the company is advancing anti-cancer therapies utilizing PD1 antibodies and regenerative medicine products like PulmonoVac®, aimed at tissue and organ regeneration. These products target a range of end-users, including healthcare providers, research institutions, and ultimately, patients seeking advanced medical treatments. The company markets its products primarily in South Korea, with potential expansion into broader Asian markets, reflecting a commitment to enhancing healthcare outcomes in these regions.The revenue model for NA Vaccine Institute is structured around B2B transactions, primarily involving partnerships with healthcare providers and institutions for the distribution of their innovative products. The company may engage in strategic collaborations with pharmaceutical distributors to facilitate access to its flagship products, including Nexavant® and PeptoVac®. Revenue is generated through direct sales to healthcare facilities and research organizations, with an emphasis on establishing long-term agreements that foster sustained use of its therapies. Pricing plans are aligned with industry standards for advanced medical products, ensuring competitive positioning within the market. Overall, NA Vaccine Institute's revenue strategy is designed to capitalize on increasing demand for innovative healthcare solutions.In November 2021, NA Vaccine Institute raised KRW 17 billion in Series B funding to enhance its research and development capabilities and expedite clinical trials. The funding will support the launch of new products, including ongoing developments in regenerative medicine. The company plans to expand its market reach into broader Asian territories by the end of 2023, increasing access to its innovative solutions, particularly in regions with high healthcare needs.

## Funding rounds

- Series B, Nov 19, 2021, $14M — Shinhan Venture Investment, Industrial Bank of Korea, DSC Investment, IMM Investment, Widwin Investment, Harang Invest, BioNote, Inc., DS Asset Management
- Seed, Jun 1, 2018 — Korea Tech Incubator for Startup, Evergreen Investment Partners

## Investors

- Korea Tech Incubator for Startup — Seed
- Evergreen Investment Partners (https://capitalatlas.ai/funds/evergreen-investment-partners) — Seed
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series B
- Industrial Bank of Korea — Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series B
- Harang Invest (https://capitalatlas.ai/funds/harang-invest) — Series B
- BioNote, Inc. — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B